search

Active clinical trials for "Chronic Urticaria"

Results 51-60 of 150

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Urticaria

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.

Completed8 enrollment criteria

A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine...

Urticaria

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.

Completed24 enrollment criteria

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less...

Allergic RhinitisChronic Urticaria

The purpose of this study is to determine the safety of the oral formulation of levocetirizine in children ages 1 to less than 6 years old who suffer from allergic rhinitis or chronic urticaria of unknown origin.

Completed23 enrollment criteria

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months...

Allergic RhinitisChronic Urticaria

To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.

Completed27 enrollment criteria

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients...

Chronic Idiopathic Urticaria

The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged 12-75 who have been diagnosed with refractory CIU and who remain symptomatic despite standard-dosed H1 antihistamine treatment.

Completed19 enrollment criteria

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Urticaria

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study after completing the 8-week treatment period.

Completed25 enrollment criteria

To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous...

Chronic Spontaneous Urticaria

A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic despite H1 antihistamine Treatment

Completed8 enrollment criteria

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).

Completed27 enrollment criteria

Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

Atopic DermatitisAtopic Dermatitis Eczema10 more

The investigational lotion is envisaged as an short- and long term "Ease & Prevent" monotherapy for adults and children with mild to moderate eczema. With itch representing the most burdensome symptom in eczema, the main objectives with the lotion is fast and efficient itch relief, high tolerability, and high short- and long term safety. This phase 1 study aims to monitor skin tolerability, and how much of the active compound that is absorbed to the bloodstream.

Completed22 enrollment criteria

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria...

Chronic Spontaneous Urticaria

A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201

Completed13 enrollment criteria
1...567...15

Need Help? Contact our team!


We'll reach out to this number within 24 hrs